112 related articles for article (PubMed ID: 9696398)
1. The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer.
Goodson WH; Moore DH; Ljung BM; Chew K; Florendo C; Mayall B; Smith HS; Waldman FM
Breast Cancer Res Treat; 1998 May; 49(2):155-64. PubMed ID: 9696398
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67.
Goodson WH; Moore DH; Ljung BM; Chew K; Mayall B; Smith HS; Waldman FM
Breast Cancer Res Treat; 2000 Jan; 59(2):113-23. PubMed ID: 10817346
[TBL] [Abstract][Full Text] [Related]
3. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
Thor AD; Liu S; Moore DH; Edgerton SM
J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587
[TBL] [Abstract][Full Text] [Related]
4. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme.
Onda K; Davis RL; Wilson CB; Hoshino T
Acta Neuropathol; 1994; 87(6):586-93. PubMed ID: 8091951
[TBL] [Abstract][Full Text] [Related]
5. Tumor labeling indices of primary breast cancers and their regional lymph node metastases.
Goodson WH; Ljung BM; Moore DH; Mayall B; Waldman FM; Chew K; Benz CC; Smith HS
Cancer; 1993 Jun; 71(12):3914-9. PubMed ID: 8508357
[TBL] [Abstract][Full Text] [Related]
6. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining.
Tsujihashi H; Nakanishi A; Matsuda H; Uejima S; Kurita T
J Urol; 1991 Apr; 145(4):846-9. PubMed ID: 2005717
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours.
Wilson GD; Saunders MI; Dische S; Daley FM; Robinson BM; Martindale CA; Joiner B; Richman PI
Cell Prolif; 1996 Mar; 29(3):141-52. PubMed ID: 8652743
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.
Struikmans H; Rutgers DH; Jansen GH; Dullens HF; Oosten L; Tulleken CA; van der Tweel I; Battermann JJ
Radiat Oncol Investig; 1999; 7(4):243-8. PubMed ID: 10492165
[TBL] [Abstract][Full Text] [Related]
9. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
Keshgegian AA; Cnaan A
Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
[TBL] [Abstract][Full Text] [Related]
10. A comparison between bromodeoxyuridine and 3H thymidine labeling in human breast tumors.
Waldman FM; Chew K; Ljung BM; Goodson W; Hom J; Duarte LA; Smith HS; Mayall B
Mod Pathol; 1991 Nov; 4(6):718-22. PubMed ID: 1724086
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferation in colorectal adenocarcinomas: comparison between Ki-67 immunostaining and bromodeoxyuridine uptake detected by immunohistochemistry and flow cytometry.
Le Pessot F; Michel P; Paresy M; Lemoine F; Hellot MF; Paillot B; Scotte M; Peillon C; Hemet J
Pathol Res Pract; 2001; 197(6):411-8. PubMed ID: 11432668
[TBL] [Abstract][Full Text] [Related]
12. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy.
Sasaki K; Matsumura K; Murakami T; Tsuji T
Oncology; 1992; 49(2):147-53. PubMed ID: 1574251
[TBL] [Abstract][Full Text] [Related]
13. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors.
Sasaki K; Matsumura K; Tsuji T; Shinozaki F; Takahashi M
Cancer; 1988 Sep; 62(5):989-93. PubMed ID: 3409179
[TBL] [Abstract][Full Text] [Related]
14. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa.
Bromley M; Rew D; Becciolini A; Balzi M; Chadwick C; Hewitt D; Li YQ; Potten CS
Eur J Histochem; 1996; 40(2):89-100. PubMed ID: 8839702
[TBL] [Abstract][Full Text] [Related]
15. In vivo measurement of breast cancer growth rate.
Goodson WH; Ljung BM; Waldman F; Mayall B; Chew K; Moore DH; Smith H; Goldman ES; Benz C
Arch Surg; 1991 Oct; 126(10):1220-3; discussion 1223-4. PubMed ID: 1929822
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells.
Bardenstein DS; Char DH; Kaleta-Michaels S; Kroll SM
Curr Eye Res; 1991 May; 10(5):479-84. PubMed ID: 1889233
[TBL] [Abstract][Full Text] [Related]
17. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
18. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade.
Weidner N; Moore DH; Ljung BM; Waldman FM; Goodson WH; Mayall B; Chew K; Smith HS
Am J Surg Pathol; 1993 Oct; 17(10):987-94. PubMed ID: 8372950
[TBL] [Abstract][Full Text] [Related]
19. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
